GlassScriptPhysician profile
William W White
NPI 1467425686
$16,487.20
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $878 · 2021: $4,375 · 2022: $8,383 · 2023: $2,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,418.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $8,000.00 | 2021-2022 | |
| Abbvie INC. | $1,672.32 | 2019-2023 | Rinvoq, Skyrizi |
| Amgen INC. | $1,149.90 | 2020-2023 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $766.34 | 2019-2023 | Cimzia |
| Novartis Pharmaceuticals Corporation | $694.00 | 2020-2023 | |
| Horizon Therapeutics Plc | $616.87 | 2020-2023 | Krystexxa |
| Janssen Biotech, INC. | $564.07 | 2020-2023 | Simponi Aria, Tremfya |
| Glaxosmithkline, LLC. | $532.69 | 2020-2023 | Benlysta |
| Pfizer INC. | $530.60 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $407.27 | 2020-2022 | |
| Genentech USA, INC. | $346.53 | 2020-2023 | Rituxan, Actemra |
| Lilly USA, LLC | $325.70 | 2020-2023 | Taltz |
| Astrazeneca Pharmaceuticals LP | $191.47 | 2021-2023 | Saphnelo |
| Allergan, INC. | $139.40 | 2019 | |
| Organon LLC | $106.22 | 2022-2023 | Renflexis, Hadlima |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $104.44 | 2022-2023 | Octagam Immune Globulin (Human) |
| Pacira Therapeutics, INC. | $90.88 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.81 | 2023 | Cyltezo, Ofev |
| Genzyme Corporation | $41.11 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $29.02 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $28.63 | 2021-2023 | Euflexxa |
| Cumberland Pharmaceuticals, INC. | $28.04 | 2022 | |
| Grt US Holding, INC. | $17.82 | 2022 | |
| Tersera Therapeutics LLC | $16.13 | 2023 | Quzyttir |
| Ultragenyx Pharmaceutical INC. | $14.74 | 2023 | |
| Fidia Pharma USA INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.